CLINICAL_TRIALS
ClinicalTrials.gov record update
Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma
This page presents selected fields from the linked source record. It does not add a medical interpretation.
Record identity and dates
- Source
- ClinicalTrials.gov
- Source record ID
- NCT06783140
- Title field or adapter rule
- protocolSection.identificationModule.officialTitle
- Ingested At
- 2026-04-25T22:28:53.288983+00:00
- Published At
- 2025-12-05T00:00:00+00:00
- Record Updated At
- 2025-12-05
- Timestamp Basis
- source retrieval time was not retained by the feed adapter
- Date limitation
- source retrieval time was not retained by the feed adapter
Fields recorded by this source
- protocolSection.conditionsModule.conditions
["Pancreatic Cancer, Advanced or Metastatic", "BRCA1/2 Mutation", "PALB2 Gene Mutation"]- protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-05"- protocolSection.identificationModule.nctId
"NCT06783140"- protocolSection.identificationModule.officialTitle
"Comparing Second-Line NABPLAGEM vs. Nab-paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma"- protocolSection.statusModule.overallStatus
"RECRUITING"- protocolSection.designModule.phases
["PHASE2", "PHASE3"]- protocolSection.statusModule.resultsFirstPostDateStruct.date
""
Study condition terms
Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.
This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.